JSF Financial LLC Takes $894,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

JSF Financial LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,993 shares of the medical equipment provider’s stock, valued at approximately $894,000.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in shares of Lantheus during the 3rd quarter valued at about $1,066,000. Massachusetts Financial Services Co. MA bought a new position in shares of Lantheus during the 3rd quarter valued at about $25,955,000. Van ECK Associates Corp boosted its position in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after purchasing an additional 21,604 shares in the last quarter. Finally, Empirical Asset Management LLC bought a new position in shares of Lantheus during the 4th quarter valued at about $323,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on LNTH shares. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Down 2.0 %

Shares of LNTH opened at $86.91 on Tuesday. Lantheus Holdings, Inc. has a 12 month low of $54.69 and a 12 month high of $126.89. The company’s fifty day moving average is $92.02 and its 200-day moving average is $98.46. The firm has a market cap of $6.04 billion, a price-to-earnings ratio of 14.46 and a beta of 0.44.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.